The drug that is being considered the next blockbuster candidate, Eisai and Biogen’s Alzheimer’s treatment ‘lecanemab,’ is set to enter the Korean market.

Eisai announced on the 8th that it had submitted an application for the marketing authorization of lecanemab to the Ministry of Food and Drug Safety to treat mild cognitive impairment or mild dementia stage of disease arising from Alzheimer’s disease (AD). This is the third application the company had filed in Asia after Japan and China.

Lecanemab was jointly developed by the two companies. Lecanemab selectively binds to neutralize and eliminate soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that are thought to contr